FR2866886B1 - Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique - Google Patents

Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique

Info

Publication number
FR2866886B1
FR2866886B1 FR0401949A FR0401949A FR2866886B1 FR 2866886 B1 FR2866886 B1 FR 2866886B1 FR 0401949 A FR0401949 A FR 0401949A FR 0401949 A FR0401949 A FR 0401949A FR 2866886 B1 FR2866886 B1 FR 2866886B1
Authority
FR
France
Prior art keywords
akylcarbamates
heteroaryl
aryl
derivatives
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0401949A
Other languages
English (en)
French (fr)
Other versions
FR2866886A1 (fr
Inventor
Ahmed Abouabdellah
Li Regine Bartsch
Christian Hoornaert
Antoine Ravet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0401949A priority Critical patent/FR2866886B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to PCT/FR2005/000451 priority patent/WO2005090292A1/fr
Priority to RSP-2010/0011A priority patent/RS51246B/sr
Priority to HK07109485.6A priority patent/HK1101759B/xx
Priority to HR20100017T priority patent/HRP20100017T1/hr
Priority to BRPI0508193-9A priority patent/BRPI0508193A/pt
Priority to PL05732902T priority patent/PL1720829T3/pl
Priority to EP09172706A priority patent/EP2251324A1/fr
Priority to NZ550008A priority patent/NZ550008A/en
Priority to AU2005223423A priority patent/AU2005223423B2/en
Priority to ZA200606724A priority patent/ZA200606724B/xx
Priority to KR1020067017250A priority patent/KR20070011297A/ko
Priority to CN2005800058656A priority patent/CN1926097B/zh
Priority to TW094105874A priority patent/TW200533637A/zh
Priority to PT05732902T priority patent/PT1720829E/pt
Priority to DK05732902.1T priority patent/DK1720829T3/da
Priority to SI200530882T priority patent/SI1720829T1/sl
Priority to EP05732902A priority patent/EP1720829B1/fr
Priority to JP2007500260A priority patent/JP4824668B2/ja
Priority to RU2006134026/04A priority patent/RU2364586C2/ru
Priority to ES05732902T priority patent/ES2334449T3/es
Priority to CA002554609A priority patent/CA2554609A1/fr
Priority to AT05732902T priority patent/ATE445592T1/de
Priority to DE602005017122T priority patent/DE602005017122D1/de
Priority to ARP050100666A priority patent/AR047973A1/es
Publication of FR2866886A1 publication Critical patent/FR2866886A1/fr
Priority to IL177329A priority patent/IL177329A/en
Priority to US11/464,355 priority patent/US7645757B2/en
Priority to MA29285A priority patent/MA28367A1/fr
Priority to NO20064329A priority patent/NO20064329L/no
Application granted granted Critical
Publication of FR2866886B1 publication Critical patent/FR2866886B1/fr
Priority to US12/625,125 priority patent/US20100069405A1/en
Priority to CY20101100030T priority patent/CY1109716T1/el
Priority to US13/156,551 priority patent/US20110237595A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0401949A 2004-02-26 2004-02-26 Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique Expired - Fee Related FR2866886B1 (fr)

Priority Applications (32)

Application Number Priority Date Filing Date Title
FR0401949A FR2866886B1 (fr) 2004-02-26 2004-02-26 Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
RSP-2010/0011A RS51246B (sr) 2004-02-26 2005-02-25 Derivati heteroarila-alkilkarbamata, njihovo dobijanje i njihova primena kao inhibitora faah enzima
HK07109485.6A HK1101759B (en) 2004-02-26 2005-02-25 Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
HR20100017T HRP20100017T1 (hr) 2004-02-26 2005-02-25 Derivati heteroaril-alkilkarbamata, postupak njihovog dobivanja i njihova upotreba kao inhibitora enzima faah
BRPI0508193-9A BRPI0508193A (pt) 2004-02-26 2005-02-25 derivados de heteroaril-alquilcarbamatos, a preparação e a aplicação como inibidores da enzima faah
PL05732902T PL1720829T3 (pl) 2004-02-26 2005-02-25 Pochodne heteroaryloalkilokarbaminianów, ich wytwarzanie i zastosowanie ich jako inhibitorów enzymu FAAH
EP09172706A EP2251324A1 (fr) 2004-02-26 2005-02-25 Dérivés d'heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
NZ550008A NZ550008A (en) 2004-02-26 2005-02-25 Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as FAAH enzyme inhibitors
AU2005223423A AU2005223423B2 (en) 2004-02-26 2005-02-25 Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as FAAH enzyme inhibitors
ZA200606724A ZA200606724B (en) 2004-02-26 2005-02-25 Derivatives of heteroaryl-alkylcarbamates, preparation method thereof and use of same as FAAH enzyme inhibitors
KR1020067017250A KR20070011297A (ko) 2004-02-26 2005-02-25 헤테로아릴-알킬카르바메이트 유도체, 그의 제조방법 및그의 ｆａａｈ 효소 억제제로서의 용도
CN2005800058656A CN1926097B (zh) 2004-02-26 2005-02-25 杂芳基-烷基氨基甲酸酯的衍生物、其制备方法和作为faah酶抑制剂的用途
TW094105874A TW200533637A (en) 2004-02-26 2005-02-25 Aryl- and heteroarylalkylcarbamate derivatives, their preparation and their application in therapeutics
PT05732902T PT1720829E (pt) 2004-02-26 2005-02-25 Derivados de heteroaril-alquilcarbamatos, sua preparação e sua aplicação como inibidores da enzima faah
DK05732902.1T DK1720829T3 (da) 2004-02-26 2005-02-25 Derivater af heteroaryl-alkylkarbamater, fremstilling heraf samt anvendelse heraf som inhibitorer af FAAH-enzym
SI200530882T SI1720829T1 (sl) 2004-02-26 2005-02-25 Derivati heteroaril-alkilkarbamatov, njihova priprava in njihova uporaba kot inhibitorji FAAH encima
PCT/FR2005/000451 WO2005090292A1 (fr) 2004-02-26 2005-02-25 Derives d’heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l’enzyme faah
EP05732902A EP1720829B1 (fr) 2004-02-26 2005-02-25 Derives d' heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
JP2007500260A JP4824668B2 (ja) 2004-02-26 2005-02-25 ヘテロアリール−アルキルカーバメート誘導体、それらの製造方法、及び、ｆａａｈ酵素インヒビターとしてのそれらの使用
ES05732902T ES2334449T3 (es) 2004-02-26 2005-02-25 Derivados de heteroaril-alquilcarbamatos, su preparacion y su aplicacion como inhibidores de la enzima faah.
CA002554609A CA2554609A1 (fr) 2004-02-26 2005-02-25 Derives d'heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
AT05732902T ATE445592T1 (de) 2004-02-26 2005-02-25 Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren
DE602005017122T DE602005017122D1 (de) 2004-02-26 2005-02-25 Derivate von heteroarylalkylcarbamaten, verfahren zu deren herstellung und deren verwendung als faah-enzyminhibitoren
RU2006134026/04A RU2364586C2 (ru) 2004-02-26 2005-02-25 Производные гетероарилалкилкарбаматов, их получение и их применение в качестве ингибиторов фермента faah
ARP050100666A AR047973A1 (es) 2004-02-26 2005-05-24 Derivados de aril - y heteroarilalquilcarbamatos, su preparacion y su aplicacion en terapeutica
IL177329A IL177329A (en) 2004-02-26 2006-08-07 Derivatives of heteroaryl-alkylcarbamates, process for the preparation thereof, pharmaceutical composition and use thereof
US11/464,355 US7645757B2 (en) 2004-02-26 2006-08-14 Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors
MA29285A MA28367A1 (fr) 2004-02-26 2006-08-22 Derives d'heteroaryl-alkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
NO20064329A NO20064329L (no) 2004-02-26 2006-09-25 Derivater av heteroaryl-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse derav som FAAH enzyminhibitorer
US12/625,125 US20100069405A1 (en) 2004-02-26 2009-11-24 Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors
CY20101100030T CY1109716T1 (el) 2004-02-26 2010-01-11 Παραγωγα ετεροαρυλ-αλκυλοκαρβονικων αλατων, η προετοιμασια τους και η εφαρμογη τους ως αναστολεις του ενζυμου faah
US13/156,551 US20110237595A1 (en) 2004-02-26 2011-06-09 Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0401949A FR2866886B1 (fr) 2004-02-26 2004-02-26 Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2866886A1 FR2866886A1 (fr) 2005-09-02
FR2866886B1 true FR2866886B1 (fr) 2007-08-31

Family

ID=34834066

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0401949A Expired - Fee Related FR2866886B1 (fr) 2004-02-26 2004-02-26 Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique

Country Status (28)

Country Link
US (3) US7645757B2 (enExample)
EP (2) EP2251324A1 (enExample)
JP (1) JP4824668B2 (enExample)
KR (1) KR20070011297A (enExample)
CN (1) CN1926097B (enExample)
AR (1) AR047973A1 (enExample)
AT (1) ATE445592T1 (enExample)
AU (1) AU2005223423B2 (enExample)
BR (1) BRPI0508193A (enExample)
CA (1) CA2554609A1 (enExample)
CY (1) CY1109716T1 (enExample)
DE (1) DE602005017122D1 (enExample)
DK (1) DK1720829T3 (enExample)
ES (1) ES2334449T3 (enExample)
FR (1) FR2866886B1 (enExample)
HR (1) HRP20100017T1 (enExample)
IL (1) IL177329A (enExample)
MA (1) MA28367A1 (enExample)
NO (1) NO20064329L (enExample)
NZ (1) NZ550008A (enExample)
PL (1) PL1720829T3 (enExample)
PT (1) PT1720829E (enExample)
RS (1) RS51246B (enExample)
RU (1) RU2364586C2 (enExample)
SI (1) SI1720829T1 (enExample)
TW (1) TW200533637A (enExample)
WO (1) WO2005090292A1 (enExample)
ZA (1) ZA200606724B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866885B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
WO2008136382A1 (ja) 2007-04-26 2008-11-13 Takeda Pharmaceutical Company Limited 二環性化合物およびその医薬用途
WO2009070497A1 (en) * 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2866734A (en) * 1956-12-05 1958-12-30 Us Vitamin Corp 3-pyridylethyl 2, 4-oxazolidinediones and process
US3054794A (en) * 1958-01-17 1962-09-18 Us Vitamin Pharm Corp Process for preparing 3-(aminoalkyl)-oxazolidine-2, 4-diones
US3742022A (en) * 1967-05-08 1973-06-26 A Verbiscar Carbamate esters of physiologically active ph enenthylamines
US3876661A (en) * 1971-03-02 1975-04-08 Anthony J Verbiscar Carbamate esters of serotonin and analogs
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
AU740588B2 (en) * 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
US6509366B2 (en) * 2000-01-18 2003-01-21 Neurogen Corporation Substituted imidazoles as selective modulators of Bradykinin B2 receptors
MXPA03009850A (es) * 2001-04-27 2004-02-12 Bristol Myers Squibb Co Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
CA2483228C (en) * 2002-04-27 2011-07-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Carboxamides
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EP1558591B1 (en) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
AU2003275493A1 (en) * 2002-10-08 2004-05-04 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US7309701B2 (en) * 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2850377B1 (fr) * 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
UA82695C2 (uk) * 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Ｃｏｘ−２及びｆａａｈ阻害剤
US7598412B2 (en) * 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
FR2866885B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
EP1574511A1 (en) * 2004-03-03 2005-09-14 Bayer CropScience S.A. 2-Pyridinylethylcarboxamide derivatives and their use as fungicides
WO2007017728A2 (en) * 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
RU2008115499A (ru) * 2005-09-22 2009-10-27 Санофи-Авентис (Fr) Новые производные аминокиламидов в качестве антагонистов лигандов рецепторов ccr3
FR2894578B1 (fr) * 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
CA2640090A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
US9549982B2 (en) * 2009-11-23 2017-01-24 Foundational Biosystems, Llc Ultra low dose nutraceutical compositions for enhancing sleep quality and treating sleep disorders

Also Published As

Publication number Publication date
TW200533637A (en) 2005-10-16
NZ550008A (en) 2010-06-25
AR047973A1 (es) 2006-03-15
ZA200606724B (en) 2007-12-27
IL177329A (en) 2012-01-31
RU2364586C2 (ru) 2009-08-20
CA2554609A1 (fr) 2005-09-29
CY1109716T1 (el) 2014-08-13
EP1720829A1 (fr) 2006-11-15
FR2866886A1 (fr) 2005-09-02
SI1720829T1 (sl) 2010-02-26
JP2007524705A (ja) 2007-08-30
EP2251324A1 (fr) 2010-11-17
HRP20100017T1 (hr) 2010-02-28
US20100069405A1 (en) 2010-03-18
AU2005223423A1 (en) 2005-09-29
DK1720829T3 (da) 2010-03-01
CN1926097A (zh) 2007-03-07
EP1720829B1 (fr) 2009-10-14
IL177329A0 (en) 2006-12-10
RS51246B (sr) 2010-12-31
BRPI0508193A (pt) 2007-08-14
US20110237595A1 (en) 2011-09-29
US20070021426A1 (en) 2007-01-25
AU2005223423B2 (en) 2011-04-14
CN1926097B (zh) 2011-06-08
RU2006134026A (ru) 2008-04-10
DE602005017122D1 (de) 2009-11-26
US7645757B2 (en) 2010-01-12
NO20064329L (no) 2006-09-25
PL1720829T3 (pl) 2010-03-31
JP4824668B2 (ja) 2011-11-30
KR20070011297A (ko) 2007-01-24
ES2334449T3 (es) 2010-03-10
MA28367A1 (fr) 2006-12-01
ATE445592T1 (de) 2009-10-15
HK1101759A1 (en) 2007-10-26
PT1720829E (pt) 2010-01-13
WO2005090292A1 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
FR2866884B1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2854158B1 (fr) Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
FR2864080B1 (fr) Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
FR2854633B1 (fr) Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
MA29017B1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2872813B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
MA28575B1 (fr) Derives de la 1-amino-phthalazine, leur preparation , et leur application en therapeutique
FR2866888B1 (fr) Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2843964B1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2882054B1 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2864958B1 (fr) Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
MA27233A1 (fr) Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique
FR2865205B1 (fr) Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2856684B1 (fr) Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2866885B1 (fr) Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
FR2882365B1 (fr) Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
FR2885364B1 (fr) Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique
FR2881744B1 (fr) Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2888847B1 (fr) Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2891828B1 (fr) Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
FR2880023B1 (fr) Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2860792B1 (fr) Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20121031